LAMPIT (nifurtimox)
Lampit helps pediatric patients, from birth to less than 18 years of age, who have Chagas disease. This medication is used for children weighing at least 2.5 kg to address infections caused by the Trypanosoma cruzi parasite. It provides a therapeutic option for managing American Trypanosomiasis in this specific population.
How LAMPIT Works
Lampit works as a nitrofuran antiprotozoal agent. This medication acts against the Trypanosoma cruzi parasite to help clear the infection from the patient's system.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2020-08-06
- Patent Cliff
- 2027
- Routes
- ORAL
- Dosage Forms
- TABLET
LAMPIT Approval History
What LAMPIT Treats
2 indicationsLAMPIT is approved for 2 conditions since its original approval in 2020. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Chagas Disease
- American Trypanosomiasis
LAMPIT Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to LAMPIT
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
3 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT00601003 results posted | V0706 | Ph 2 | completed | Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma |
| NCT03981523 TESEO | 743474 U01AI129783 | Ph 2 | completed | New Therapies and Biomarkers for Chagas Infection |
| NCT01685827 | DNDiFEX004 | Ph 2, Ph 3 | completed | Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2 |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
LAMPIT FDA Label Details
Indications & Usage
FDA Label (PDF)LAMPIT is indicated for the treatment of Chagas Disease; American Trypanosomiasis.
LAMPIT Patents & Exclusivity
Exclusivity
Track LAMPIT with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment